Step two: explore the appeals process If your coverage was removed, you may have grounds for appeal, particularly if you have documented medical necessity beyond weight management alone
January 2024: The FDA said it was evaluating reports of hair loss, suicidal thoughts and aspiration under sedation and anesthesia among people taking Ozempic and similar diabetes and weight loss medications
Veterans Affairs data found that adults with type 2 diabetes who stayed on GLP-1 drugs for three years had the greatest reduction in heart attack, stroke or death compared with those on sulfonylureas, an older class of medication, and that even brief periods of discontinuations or interruptions might progressively erode and could ultimately reverse this protection. A Reuters Health summary of the same work reported that patients who remained on GLP-1s continuously saw an 18 percent reduction in cardiovascular risk versus sulfonylureas, while stopping for as little as six months raised risk by four percent and two years off treatment raised risk by 22 percent, compared with continuous use
GLP-1 receptor (GLP-1R) agonists, originally developed for glycemic control in patients with type 2 DM (T2DM), have demonstrated broad mechanistic versatility, enabling their application across a spectrum of cardiometabolic disorders
Oral medication still provides a practical alternative for individuals who prefer tablets and can maintain consistent dosing habits
